Enzymatica Publ Ab Stock Beta
| ENZY Stock | SEK 1.74 0.07 4.19% |
Enzymatica publ AB fundamentals help investors to digest information that contributes to Enzymatica Publ's financial success or failures. It also enables traders to predict the movement of Enzymatica Stock. The fundamental analysis module provides a way to measure Enzymatica Publ's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enzymatica Publ stock.
Enzymatica |
Enzymatica publ AB Company Beta Analysis
Enzymatica Publ's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Enzymatica Publ Beta | 0.088 |
Most of Enzymatica Publ's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enzymatica publ AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Enzymatica publ AB has a Beta of 0.088. This is 89.77% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all Sweden stocks is 158.67% lower than that of the firm.
Enzymatica Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enzymatica Publ's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enzymatica Publ could also be used in its relative valuation, which is a method of valuing Enzymatica Publ by comparing valuation metrics of similar companies.Enzymatica Publ is currently under evaluation in beta category among its peers.
As returns on the market increase, Enzymatica Publ's returns are expected to increase less than the market. However, during the bear market, the loss of holding Enzymatica Publ is expected to be smaller as well.
Enzymatica Fundamentals
| Return On Equity | -0.4 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.12) % | |||
| Operating Margin | (1.12) % | |||
| Current Valuation | 613.36 M | |||
| Shares Outstanding | 164.26 M | |||
| Shares Owned By Insiders | 64.15 % | |||
| Shares Owned By Institutions | 1.71 % | |||
| Price To Earning | (6.00) X | |||
| Price To Book | 47.25 X | |||
| Price To Sales | 14.29 X | |||
| Revenue | 57.24 M | |||
| Gross Profit | 33.35 M | |||
| EBITDA | (38.19 M) | |||
| Net Income | (45.39 M) | |||
| Cash And Equivalents | 64.82 M | |||
| Cash Per Share | 0.44 X | |||
| Total Debt | 1.12 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 2.08 X | |||
| Book Value Per Share | 0.91 X | |||
| Cash Flow From Operations | (35.87 M) | |||
| Earnings Per Share | (0.37) X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 23 | |||
| Beta | 0.088 | |||
| Market Capitalization | 681.8 M | |||
| Total Asset | 157.04 M | |||
| Working Capital | 64 M | |||
| Current Asset | 81 M | |||
| Current Liabilities | 17 M | |||
| Net Asset | 157.04 M |
About Enzymatica Publ Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enzymatica publ AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enzymatica Publ using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enzymatica publ AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enzymatica Stock Analysis
When running Enzymatica Publ's price analysis, check to measure Enzymatica Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzymatica Publ is operating at the current time. Most of Enzymatica Publ's value examination focuses on studying past and present price action to predict the probability of Enzymatica Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzymatica Publ's price. Additionally, you may evaluate how the addition of Enzymatica Publ to your portfolios can decrease your overall portfolio volatility.